Shufeng Xingbi Therapy in Allergic Rhinitis: Immune and Microbiota Modulation Revealed

Study Background and Research Question

Allergic rhinitis (AR) is a prevalent, chronic inflammatory condition of the nasal mucosa, often triggered by environmental allergens and mediated through immunoglobulin E (IgE) responses. With global rates exceeding 10%, AR imposes a substantial burden on quality of life and health systems. The underlying pathogenesis is increasingly attributed to an imbalance in T helper 1 (Th1) and T helper 2 (Th2) immune responses, alongside disruptions in the gut microbiota—a relationship supported by the "hygiene hypothesis" and accumulating clinical observations. Standard treatments, including antihistamines and glucocorticoids, address symptoms but are limited by adverse effects and inadequate long-term immune regulation.

Within this context, the reference study (Yan et al., 2025) investigates Shufeng Xingbi Therapy (SFXBT), a traditional Chinese medicine regimen, for its capacity to correct Th1/Th2 imbalance and restore gut microbial homeostasis in an ovalbumin (OVA)-induced rat model of AR. The central research question: Can SFXBT mitigate allergic inflammation in AR by modulating both systemic immunity and the composition of intestinal flora?

Key Innovation from the Reference Study

The principal innovation lies in the dual investigation of immune and microbiome endpoints within a controlled in vivo AR model. While previous work has separately explored immune modulation or microbial shifts, this study integrates both domains, leveraging advanced molecular and microbiological techniques to elucidate how SFXBT may concurrently rebalance Th1/Th2 responses and reshape gut microbial communities. This holistic approach offers a mechanistic bridge between mucosal immunity and microbial ecology, rarely achieved in prior AR research.

Methods and Experimental Design Insights

The study utilized 32 male Sprague-Dawley rats, randomly assigned to four groups: control, OVA-induced AR, antibiotic + SFXBT, and acetic acid + SFXBT. Allergic rhinitis was induced via repeated ovalbumin sensitization and challenge, a widely accepted method for recapitulating key features of human AR.

Therapeutic intervention involved oral administration of SFXBT combined with topical Xingbi gel nasal drops. The antibiotic group received a broad-spectrum regimen to perturb baseline microbiota, providing a model for dissecting microbiota-mediated effects. Outcomes were assessed through a comprehensive suite of methods:

• AR behavioral scoring (sneezing, nasal rubbing, etc.)
• Histopathological evaluation of nasal mucosa using hematoxylin & eosin (H&E) staining
• 16S rDNA sequencing of colonic contents to profile microbial shifts
• Quantification of serum IgE and interleukin-4 (IL-4) by ELISA
• Measurement of short-chain fatty acids (SCFAs) in colon samples
• RT-qPCR for mRNA expression of STAT5, STAT6, and GATA3 in nasal tissue
• Western blot analysis for corresponding protein levels

This integrative design enabled the authors to connect behavioral, immunological, and microbiological changes within the same experimental framework.

Core Findings and Why They Matter

The SFXBT intervention yielded several notable outcomes, each with mechanistic and translational significance:

• Reduction in Allergic Symptoms: Both SFXBT-treated groups (antibiotic + SFXBT and acetic acid + SFXBT) exhibited significant decreases in AR behavioral scores compared to the OVA group (P < 0.01), paralleled by amelioration of nasal mucosal pathology (Yan et al., 2025).
• Immune Modulation: SFXBT led to marked reductions in serum IgE and IL-4 levels (P < 0.05), implicating suppressed Th2 dominance. Downregulation of STAT5, STAT6, and GATA3 mRNA and protein in nasal tissue further supported restoration of Th1/Th2 balance.
• Microbiota Remodeling: 16S rDNA sequencing revealed a significant increase in Firmicutes and a decrease in Bacteroidetes at the phylum level. At the genus level, Lactobacillus, Romboutsia, Allobaculum, and Dubosiella populations were enriched post-SFXBT treatment, suggesting a shift toward a more anti-inflammatory microbiota profile.
• Enhanced SCFA Production: The SFXBT groups displayed elevated levels of colonic SCFAs, metabolites known to support regulatory immune responses and barrier function.

These findings collectively indicate that SFXBT's efficacy is not limited to symptomatic relief; it orchestrates a systemic shift in immune and microbial parameters linked to disease pathogenesis. This dual action is particularly relevant given the growing emphasis on the gut-lung axis in allergic and inflammatory disorders.

Comparison with Existing Internal Articles

Several internal resources contextualize and extend the study's insights, particularly regarding experimental modulation of microbiota and immune pathways:

• The article "Vancomycin in Immune-Microbiota Modulation: Beyond Bacter..." discusses how Vancomycin, a glycopeptide antibiotic, is used to manipulate gut microbiota and probe host immune responses in models of bacterial resistance and immune interaction. The reference study's use of antibiotics to perturb baseline flora mirrors such strategies, reinforcing the utility of glycopeptide antibiotics as research tools in delineating microbiome-immune mechanisms.
• "Vancomycin: Glycopeptide Antibiotic Workflows for MRSA Research" provides protocols for leveraging high-purity Vancomycin in infection and microbiota research. These workflows align with the reference paper's antibiotic intervention arm, supporting the role of precise antibacterial agents in dissecting microbial contributions to immune-mediated disease.

The reference paper’s integrative approach—combining immune, microbial, and behavioral metrics—sets a benchmark for future studies examining not only antimicrobial efficacy but also downstream effects on host immunity.

Limitations and Transferability

While the findings are compelling, several limitations merit consideration:

• Species and Model Constraints: The study was conducted in male rats; differences in immune and microbial responses by sex or species may limit direct extrapolation to human AR.
• Antibiotic Regimen Specificity: The broad-spectrum antibiotic protocol may not capture the more targeted effects of specific agents such as glycopeptide antibiotics, including Vancomycin, on defined microbiota populations.
• Duration and Long-Term Effects: The short-term intervention window precludes assessment of sustained immune and microbial remodeling.
• Mechanistic Depth: While correlations between immune parameters and microbial shifts are demonstrated, direct causal links require further validation, for example via gnotobiotic models or targeted metabolomics.

Nonetheless, the study offers a robust proof-of-concept for integrating immune and microbiota endpoints in AR research, with methodological frameworks transferable to other models of immune-mediated disease.

Protocol Parameters

• OVA Sensitization: Typically performed with 1 mg/mL ovalbumin (OVA) plus adjuvant, administered intraperitoneally on days 0 and 7, followed by intranasal challenge from day 14 onward.
• Antibiotic Pre-treatment: Broad-spectrum antibiotics are generally administered via drinking water for 7–14 days prior to allergen challenge to induce microbiota depletion.
• SFXBT Administration: Oral dosing and topical nasal application, with dosages matched to body weight and frequency as described in the reference protocol.
• Behavioral Scoring: Quantify sneezing and nasal rubbing episodes in a standardized observation window post-challenge.
• Microbiota Profiling: Extract colonic content DNA for 16S rDNA sequencing, targeting V3–V4 regions for genus-level resolution.

Researchers should adapt these parameters based on animal facility constraints and desired mechanistic endpoints.

Research Support Resources

For those seeking to replicate or extend microbiota-immune interaction studies, precise modulation of gut flora is critical. Glycopeptide antibiotics such as Vancomycin (SKU C6417) are widely used to selectively target Gram-positive bacteria, enabling controlled investigation of peptidoglycan precursor binding and its downstream immunological effects. APExBIO supplies high-purity Vancomycin suitable for research into bacterial resistance mechanisms and the interplay between the microbiome and host immunity, as highlighted in both the reference study and internal articles. Proper use of Vancomycin can help delineate the relative contributions of microbial taxa to disease processes, particularly in MRSA and Clostridium difficile infection research.

Outlook

The findings of Yan et al., 2025 underscore the importance of integrating immunological and microbiological endpoints in allergy research. As protocols evolve, leveraging defined antibacterial agents and multi-omic profiling will clarify the causal relationships underpinning immune-microbiota crosstalk. This integrated perspective is essential for developing targeted, durable interventions in allergic and other immune-mediated diseases.